Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,965.31 (-1.51%)
DOW   33,887.14 (-1.34%)
QQQ   282.65 (-1.49%)
AAPL   143.75 (-2.94%)
MSFT   241.25 (-2.52%)
META   109.03 (-2.14%)
GOOGL   95.73 (-1.78%)
AMZN   93.78 (+0.40%)
TSLA   183.11 (+0.14%)
NVDA   159.24 (-2.13%)
NIO   10.22 (+0.49%)
BABA   75.80 (+0.40%)
AMD   73.05 (-2.78%)
T   18.83 (-1.52%)
MU   55.93 (-4.25%)
CGC   3.41 (-6.83%)
F   13.71 (-2.63%)
GE   85.84 (-2.61%)
DIS   95.84 (-3.06%)
AMC   7.13 (-5.06%)
PYPL   80.24 (+0.20%)
PFE   49.41 (+0.41%)
NFLX   281.71 (-1.34%)
S&P 500   3,965.31 (-1.51%)
DOW   33,887.14 (-1.34%)
QQQ   282.65 (-1.49%)
AAPL   143.75 (-2.94%)
MSFT   241.25 (-2.52%)
META   109.03 (-2.14%)
GOOGL   95.73 (-1.78%)
AMZN   93.78 (+0.40%)
TSLA   183.11 (+0.14%)
NVDA   159.24 (-2.13%)
NIO   10.22 (+0.49%)
BABA   75.80 (+0.40%)
AMD   73.05 (-2.78%)
T   18.83 (-1.52%)
MU   55.93 (-4.25%)
CGC   3.41 (-6.83%)
F   13.71 (-2.63%)
GE   85.84 (-2.61%)
DIS   95.84 (-3.06%)
AMC   7.13 (-5.06%)
PYPL   80.24 (+0.20%)
PFE   49.41 (+0.41%)
NFLX   281.71 (-1.34%)
S&P 500   3,965.31 (-1.51%)
DOW   33,887.14 (-1.34%)
QQQ   282.65 (-1.49%)
AAPL   143.75 (-2.94%)
MSFT   241.25 (-2.52%)
META   109.03 (-2.14%)
GOOGL   95.73 (-1.78%)
AMZN   93.78 (+0.40%)
TSLA   183.11 (+0.14%)
NVDA   159.24 (-2.13%)
NIO   10.22 (+0.49%)
BABA   75.80 (+0.40%)
AMD   73.05 (-2.78%)
T   18.83 (-1.52%)
MU   55.93 (-4.25%)
CGC   3.41 (-6.83%)
F   13.71 (-2.63%)
GE   85.84 (-2.61%)
DIS   95.84 (-3.06%)
AMC   7.13 (-5.06%)
PYPL   80.24 (+0.20%)
PFE   49.41 (+0.41%)
NFLX   281.71 (-1.34%)
S&P 500   3,965.31 (-1.51%)
DOW   33,887.14 (-1.34%)
QQQ   282.65 (-1.49%)
AAPL   143.75 (-2.94%)
MSFT   241.25 (-2.52%)
META   109.03 (-2.14%)
GOOGL   95.73 (-1.78%)
AMZN   93.78 (+0.40%)
TSLA   183.11 (+0.14%)
NVDA   159.24 (-2.13%)
NIO   10.22 (+0.49%)
BABA   75.80 (+0.40%)
AMD   73.05 (-2.78%)
T   18.83 (-1.52%)
MU   55.93 (-4.25%)
CGC   3.41 (-6.83%)
F   13.71 (-2.63%)
GE   85.84 (-2.61%)
DIS   95.84 (-3.06%)
AMC   7.13 (-5.06%)
PYPL   80.24 (+0.20%)
PFE   49.41 (+0.41%)
NFLX   281.71 (-1.34%)
NASDAQ:ACOR

Acorda Therapeutics - ACOR Stock Forecast, Price & News

$0.64
+0.03 (+4.58%)
(As of 11/28/2022 11:59 AM ET)
Add
Compare
Today's Range
$0.61
$0.64
50-Day Range
$0.28
$1.07
52-Week Range
$0.26
$3.05
Volume
4,518 shs
Average Volume
1.62 million shs
Market Capitalization
$15.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ACOR stock logo

About Acorda Therapeutics (NASDAQ:ACOR) Stock

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

Receive ACOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACOR Stock News Headlines

Acorda Therapeutics Misses Q2 EPS by $2.79
See More Headlines
Receive ACOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acorda Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ACOR Company Calendar

Last Earnings
11/09/2021
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/08/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ACOR
CUSIP
00484M10
Employees
118
Year Founded
1995

Profitability

Net Income
$-103,950,000.00
Pretax Margin
-70.87%

Debt

Sales & Book Value

Annual Sales
$129.07 million
Book Value
$13.49 per share

Miscellaneous

Free Float
23,768,000
Market Cap
$15.48 million
Optionable
Optionable
Beta
1.64

Social Links


Key Executives

  • Dr. Ron Cohen M.D. (Age 66)
    Founder, CEO, Pres & Director
    Comp: $1.21M
  • Dr. Burkhard Blank M.D. (Age 67)
    Interim Head of Drug Safety
    Comp: $1.36M
  • Mr. Michael A. Gesser M.B.A. (Age 59)
    Chief Financial Officer
  • Mr. Robert Morales (Age 54)
    Interim Principal Accounting Officer, Principal Financial Officer, VP of Fin. & Controller
  • Ms. Felicia Vonella
    VP of Investor Relations
  • Mr. Neil S. Belloff Esq. (Age 62)
    Gen. Counsel & Corp. Sec.
  • Ms. Tierney Saccavino
    Exec. VP of Corp. Communications
  • Ms. Denise J. Duca
    Exec. VP of HR
  • Mr. Andrew Mayer J.D.
    Sr. VP
  • Mr. Kerry M. Clem (Age 52)
    Chief Commercial Officer













ACOR Stock - Frequently Asked Questions

How have ACOR shares performed in 2022?

Acorda Therapeutics' stock was trading at $2.39 on January 1st, 2022. Since then, ACOR stock has decreased by 74.5% and is now trading at $0.6096.
View the best growth stocks for 2022 here
.

When is Acorda Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 8th 2023.
View our ACOR earnings forecast
.

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics, Inc. (NASDAQ:ACOR) posted its earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($1.43) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.56) by $0.13. The biopharmaceutical company had revenue of $31.46 million for the quarter, compared to analysts' expectations of $30.57 million. Acorda Therapeutics had a negative trailing twelve-month return on equity of 96.44% and a negative net margin of 85.97%.

When did Acorda Therapeutics' stock split?

Shares of Acorda Therapeutics reverse split on the morning of Monday, January 4th 2021. The 1-6 reverse split was announced on Thursday, December 31st 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 31st 2020. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

What guidance has Acorda Therapeutics issued on next quarter's earnings?

Acorda Therapeutics updated its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $116.00 million-$119.70 million, compared to the consensus revenue estimate of $120.51 million.

What is Ron Cohen's approval rating as Acorda Therapeutics' CEO?

39 employees have rated Acorda Therapeutics Chief Executive Officer Ron Cohen on Glassdoor.com. Ron Cohen has an approval rating of 55% among the company's employees. This puts Ron Cohen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Acorda Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), InterDigital (IDCC), Nektar Therapeutics (NKTR), Rigel Pharmaceuticals (RIGL), Novan (NOVN), SCYNEXIS (SCYX), Acasti Pharma (ACST) and Applied Materials (AMAT).

What is Acorda Therapeutics' stock symbol?

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

Who are Acorda Therapeutics' major shareholders?

Acorda Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (3.52%). Insiders that own company stock include Jane Wasman and Ron Cohen.
View institutional ownership trends
.

How do I buy shares of Acorda Therapeutics?

Shares of ACOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acorda Therapeutics' stock price today?

One share of ACOR stock can currently be purchased for approximately $0.61.

How much money does Acorda Therapeutics make?

Acorda Therapeutics (NASDAQ:ACOR) has a market capitalization of $14.80 million and generates $129.07 million in revenue each year. The biopharmaceutical company earns $-103,950,000.00 in net income (profit) each year or ($7.01) on an earnings per share basis.

How many employees does Acorda Therapeutics have?

The company employs 118 workers across the globe.

How can I contact Acorda Therapeutics?

Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The official website for the company is www.acorda.com. The biopharmaceutical company can be reached via phone at (914) 347-4300 or via fax at 914-347-4560.

This page (NASDAQ:ACOR) was last updated on 11/28/2022 by MarketBeat.com Staff